Concepts (75)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tetracyclines | 3 | 2019 | 22 | 1.340 |
Why?
|
| Anti-Bacterial Agents | 8 | 2019 | 2578 | 0.800 |
Why?
|
| Topoisomerase II Inhibitors | 2 | 2014 | 15 | 0.210 |
Why?
|
| Cytochrome P-450 CYP3A Inducers | 1 | 2019 | 1 | 0.160 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2019 | 11 | 0.160 |
Why?
|
| Itraconazole | 1 | 2019 | 24 | 0.150 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2019 | 60 | 0.150 |
Why?
|
| Half-Life | 1 | 2018 | 162 | 0.150 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 153 | 0.150 |
Why?
|
| Rifampin | 1 | 2019 | 136 | 0.140 |
Why?
|
| Drug Interactions | 1 | 2019 | 261 | 0.140 |
Why?
|
| Area Under Curve | 1 | 2018 | 333 | 0.140 |
Why?
|
| Anthrax | 1 | 2017 | 31 | 0.140 |
Why?
|
| Bacillus anthracis | 1 | 2017 | 40 | 0.140 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2017 | 834 | 0.130 |
Why?
|
| Amino Acid Isomerases | 1 | 2015 | 7 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1740 | 0.110 |
Why?
|
| Azepines | 1 | 2015 | 65 | 0.110 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1665 | 0.110 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 294 | 0.110 |
Why?
|
| Naphthyridines | 1 | 2014 | 10 | 0.110 |
Why?
|
| Morpholines | 1 | 2014 | 64 | 0.110 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2012 | 230 | 0.100 |
Why?
|
| Pyridines | 1 | 2015 | 250 | 0.100 |
Why?
|
| Organic Chemicals | 1 | 2012 | 60 | 0.100 |
Why?
|
| Dioxanes | 1 | 2012 | 5 | 0.100 |
Why?
|
| Quinolones | 1 | 2012 | 58 | 0.100 |
Why?
|
| DNA Ligases | 1 | 2010 | 17 | 0.090 |
Why?
|
| Piperidines | 1 | 2012 | 240 | 0.080 |
Why?
|
| Middle Aged | 2 | 2019 | 29399 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 609 | 0.070 |
Why?
|
| Adult | 2 | 2019 | 31945 | 0.070 |
Why?
|
| Helicobacter pylori | 1 | 2015 | 1335 | 0.060 |
Why?
|
| Female | 5 | 2019 | 71928 | 0.060 |
Why?
|
| Helicobacter Infections | 1 | 2015 | 1278 | 0.060 |
Why?
|
| Young Adult | 1 | 2018 | 9944 | 0.050 |
Why?
|
| DNA Topoisomerase IV | 2 | 2014 | 13 | 0.050 |
Why?
|
| Staphylococcal Infections | 3 | 2012 | 573 | 0.050 |
Why?
|
| Male | 2 | 2019 | 66127 | 0.050 |
Why?
|
| Adolescent | 1 | 2018 | 20624 | 0.040 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 11 | 0.040 |
Why?
|
| Spores, Bacterial | 1 | 2017 | 24 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2017 | 89 | 0.030 |
Why?
|
| Humans | 3 | 2019 | 134156 | 0.030 |
Why?
|
| Mice | 4 | 2017 | 19055 | 0.030 |
Why?
|
| Bacterial Toxins | 1 | 2017 | 177 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 320 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 407 | 0.030 |
Why?
|
| Peptidoglycan | 1 | 2015 | 22 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 1089 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 825 | 0.030 |
Why?
|
| DNA Gyrase | 1 | 2014 | 27 | 0.030 |
Why?
|
| Amoxicillin | 1 | 2015 | 125 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 2014 | 74 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2017 | 497 | 0.030 |
Why?
|
| Fluoroquinolones | 1 | 2014 | 97 | 0.030 |
Why?
|
| Kinetics | 1 | 2015 | 1357 | 0.020 |
Why?
|
| ERG1 Potassium Channel | 1 | 2012 | 4 | 0.020 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2012 | 9 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 2012 | 171 | 0.020 |
Why?
|
| Animals | 4 | 2017 | 36557 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2012 | 119 | 0.020 |
Why?
|
| Biological Availability | 1 | 2012 | 153 | 0.020 |
Why?
|
| Survival Rate | 1 | 2017 | 2218 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 2015 | 493 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 1310 | 0.020 |
Why?
|
| Dogs | 1 | 2012 | 798 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 611 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 727 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2012 | 385 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2014 | 1027 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2010 | 383 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 3890 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2010 | 480 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4808 | 0.020 |
Why?
|